ELA takes heart failure CRT (cardiac resynchronisation therapy) device to EU:
This article was originally published in Clinica
Executive Summary
ELA Medical, a Sorin Group company, has launched in Europe its ALTO 2 MSP 627 cardiac resynchronisation therapy (CRT) defibrillator for treating heart failure. The device, which complements ELA's CRT product line, incorporates therapies both for heart failure patients and for sudden cardiac death prevention, including ELA's proprietary PARAD/PARAD+ arrhythmia discrimination that identifies and analyses complex arrhythmias, and a fully configurable biventricular function with programmable ventricle-to-ventricle delay and independent left ventricular output.